CRIS Current Research Information System

IELASI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.237
NA - Nord America 1.416
EU - Europa 945
AF - Africa 106
SA - Sud America 86
OC - Oceania 2
Totale 4.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.382
VN - Vietnam 705
CN - Cina 544
SG - Singapore 535
IT - Italia 335
HK - Hong Kong 150
DE - Germania 135
SE - Svezia 79
KR - Corea 73
GB - Regno Unito 69
IN - India 62
NL - Olanda 58
BR - Brasile 50
FI - Finlandia 48
IE - Irlanda 48
FR - Francia 42
TG - Togo 38
BD - Bangladesh 37
JP - Giappone 30
RU - Federazione Russa 28
AT - Austria 26
CA - Canada 22
ZA - Sudafrica 19
AR - Argentina 18
PH - Filippine 16
ID - Indonesia 15
SC - Seychelles 14
TH - Thailandia 11
BG - Bulgaria 10
MX - Messico 9
PK - Pakistan 9
CI - Costa d'Avorio 8
TR - Turchia 8
CH - Svizzera 7
ES - Italia 7
LT - Lituania 7
NG - Nigeria 7
PL - Polonia 7
UA - Ucraina 7
HR - Croazia 6
IQ - Iraq 6
MA - Marocco 6
BE - Belgio 5
EC - Ecuador 5
JO - Giordania 5
MK - Macedonia 5
TW - Taiwan 5
DZ - Algeria 4
PS - Palestinian Territory 4
VE - Venezuela 4
CL - Cile 3
CZ - Repubblica Ceca 3
EE - Estonia 3
MY - Malesia 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
HU - Ungheria 2
IR - Iran 2
KZ - Kazakistan 2
LB - Libano 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TN - Tunisia 2
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
CM - Camerun 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
JM - Giamaica 1
KE - Kenya 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MR - Mauritania 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
RS - Serbia 1
SV - El Salvador 1
TV - Tuvalu 1
Totale 4.792
Salva come PNG Salva come JPEG
Città #
Singapore 379
Ashburn 230
Ho Chi Minh City 203
Hanoi 183
Hefei 157
Hong Kong 133
San Jose 132
Bologna 101
Chandler 78
Santa Clara 76
Fairfield 66
Seoul 62
Boardman 52
Beijing 50
Southend 50
Los Angeles 49
Dublin 48
Dallas 42
Council Bluffs 41
New York 41
Helsinki 38
Lomé 38
Da Nang 35
Milan 28
Princeton 28
Munich 26
Haiphong 25
Houston 24
Rome 24
Tokyo 24
Lauterbourg 23
Frankfurt am Main 22
Dong Ket 21
Wilmington 21
Vienna 20
Woodbridge 19
Amsterdam 15
Seattle 15
Bengaluru 14
Cambridge 14
Orem 14
Redondo Beach 14
Guangzhou 13
Johannesburg 13
Ann Arbor 12
Hải Dương 11
Chicago 10
Falkenstein 10
Jakarta 10
Nuremberg 10
Sofia 10
Des Moines 9
Falls Church 9
San Francisco 9
San Giovanni in Persiceto 9
Thái Nguyên 9
Abidjan 8
Berlin 8
Buffalo 8
Can Tho 8
Shanghai 8
Shenzhen 8
Toronto 8
Bern 7
Brooklyn 7
London 7
Nanjing 7
São Paulo 7
Abeokuta 6
Lahore 6
Montreal 6
Ninh Bình 6
Shenyang 6
Turin 6
Washington 6
Amman 5
Biên Hòa 5
Denver 5
Ha Long 5
Lappeenranta 5
Naples 5
Phoenix 5
Skopje 5
Tongling 5
Turku 5
Verona 5
Warsaw 5
Westminster 5
Bremen 4
Brussels 4
Bắc Giang 4
Bắc Ninh 4
Bến Tre 4
Chennai 4
Florence 4
Genoa 4
Hangzhou 4
Long Xuyen 4
Manila 4
Mountain View 4
Totale 3.065
Salva come PNG Salva come JPEG
Nome #
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 257
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 209
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 202
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib 185
Donafenib in hepatocellular carcinoma 181
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 176
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 162
TKIs in combination with immunotherapy for hepatocellular carcinoma 160
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 157
Natural history of hypovascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced mr imaging in cirrhotic patients during surveillance program 156
Treatment of combined hepatocellular and cholangiocarcinoma 155
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib 152
Outcome of hepatic resection for HCC in ideal and non-ideal candidates 151
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 151
Experience with regorafenib in the treatment of hepatocellular carcinoma 149
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 146
Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia 139
A case of Leishmania infection with focal splanchnic involvement without systemic symptoms: a potential anti-inflammatory role for vitamin D 126
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery 124
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 124
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy 121
Lenvatinib mesylate to treat hepatocellular carcinoma 119
Hot topics in hepatocellular carcinoma 117
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 117
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 115
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 105
Anabolic Androgenic Steroids and Hepatocellular Adenoma and Carcinoma: Molecular Mechanisms and Clinical Implications 103
A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival 99
An update on atezolizumab for hepatocellular carcinoma 95
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 82
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma 78
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study 72
Totale 4.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.203
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.203
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202137 0 0 0 0 0 0 0 0 0 0 0 37
2021/2022314 10 1 19 8 29 18 8 35 22 13 105 46
2022/2023358 26 54 13 39 40 27 32 19 61 5 9 33
2023/2024210 7 26 14 14 39 43 10 13 14 10 12 8
2024/2025948 36 65 73 75 106 34 111 37 29 64 76 242
2025/20262.813 242 219 169 159 195 75 541 126 563 196 133 195
Totale 4.903